Robert Barrow Sells 19,023 Shares of Definium Therapeutics (NASDAQ:DFTX) Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) CEO Robert Barrow sold 19,023 shares of the company’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $37.94, for a total value of $721,732.62. Following the completion of the transaction, the chief executive officer directly owned 1,494,640 shares in the company, valued at approximately $56,706,641.60. This trade represents a 1.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Robert Barrow also recently made the following trade(s):

• On Thursday, June 25th, Robert Barrow sold 29,208 shares of Definium Therapeutics stock. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24.

Definium Therapeutics Stock Up 0.2%

Definium Therapeutics stock opened at $38.09 on Friday. The firm has a 50 day moving average price of $43.70 and a 200 day moving average price of $29.49. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. Definium Therapeutics, Inc. has a fifty-two week low of $8.77 and a fifty-two week high of $49.70. The company has a market capitalization of $5.12 billion, a PE ratio of -11.10 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). Research analysts expect that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current year.

Hedge Funds Weigh In On Definium Therapeutics

Several large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. lifted its holdings in shares of Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares during the last quarter. Nykredit A S purchased a new position in Definium Therapeutics during the 2nd quarter worth approximately $45,000. BNP Paribas Financial Markets increased its position in Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after buying an additional 3,020 shares during the period. Caxton Associates LLP acquired a new position in Definium Therapeutics during the third quarter worth approximately $126,000. Finally, ExodusPoint Capital Management LP purchased a new stake in Definium Therapeutics in the fourth quarter valued at approximately $254,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Analyst Ratings Changes

DFTX has been the subject of a number of analyst reports. Canaccord Genuity Group set a $64.00 target price on shares of Definium Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 13th. Bank of America started coverage on Definium Therapeutics in a report on Tuesday, August 18th. They set a “buy” rating and a $75.00 price target for the company. Maxim Group set a $55.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a report on Friday, August 14th. Leerink Partners set a $52.00 target price on Definium Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $70.00 price target on shares of Definium Therapeutics in a report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $63.00.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.